PGT-SR: What It Tests and How It Relates to Chromosome Rearrangements

A couple learns from a blood test that one of them carries a balanced translocation. They have been trying to conceive, and a clinician mentions PGT-SR as one option in an IVF cycle. The name is unfamiliar, and it is easy to assume it is simply a stronger version of the chromosome screening offered to everyone. It is not. PGT-SR is a targeted test, and understanding what it is built to look for — and what it is not built to look for — is the first step in deciding whether it belongs in your plan.

What PGT-SR stands for and what it is designed to do

PGT-SR means preimplantation genetic testing for chromosomal structural rearrangements. The HFEA describes it as testing that concerns chromosomal structural rearrangements, and it is distinct from PGT-M, which concerns a known monogenic (single-gene) condition. The two tests answer different questions, and a treating team together with a genetic counsellor should discuss the relevant history, the test design and whether testing is suitable.

In practice, PGT-SR is used when a structural rearrangement has already been identified in a parent — usually through a karyotype, a chromosome analysis done on a blood sample. The test then examines cells taken from an embryo during an IVF cycle to see whether that embryo has inherited the rearrangement in a balanced or unbalanced form. It is not a general screen for every possible chromosome problem; it is built around one known finding in the family.

What counts as a structural rearrangement

Chromosomes are long packages of DNA. A structural rearrangement means that pieces of one or more chromosomes have been broken and rejoined in an unusual arrangement. Several types are relevant to PGT-SR:

• Reciprocal translocation — two different chromosomes have exchanged segments. A carrier can be healthy because no genetic material is obviously missing or extra, but the way the chromosomes pair and separate during egg or sperm formation can produce unbalanced embryos.
• Robertsonian translocation — two chromosomes that normally exist separately have joined end to end. This involves a particular group of chromosomes, and carriers can be healthy while their reproductive risk differs from that of other translocation carriers.
• Inversion — a segment of a single chromosome has been flipped and reinserted. Depending on the details, this can affect how the chromosome behaves during meiosis.
• Unbalanced derivatives — the outcome the test is chiefly trying to identify: an embryo that carries a rearranged chromosome with missing or extra material, which is the situation associated with the reproductive concerns that prompted testing.

These categories are not interchangeable. The exact chromosomes involved, the size and position of the segments, and whether the carrier is the mother or the father all shape what the laboratory needs to design and what the counselling discussion covers.

How PGT-SR differs from PGT-A and PGT-M

The three tests are often mentioned together, which can make them sound like tiers of the same product. Their purposes are different:

Test	What it addresses	What it is built around
PGT-A	Chromosome number in the embryo sample	A general assessment of chromosome copy number, with recognised limitations and the possibility of incorrect findings
PGT-M	A known single-gene condition in the family	A specific inherited condition and its genetic basis
PGT-SR	A known structural rearrangement in a parent	The particular rearrangement, characterised in advance so the test can target it

PGT-A assesses chromosome number in cells sampled from an embryo, and the HFEA notes that testing has limitations and can produce incorrect findings. PGT-M concerns a known monogenic condition. PGT-SR concerns chromosomal structural rearrangements. Because the questions differ, the laboratory work differs too: PGT-SR has to be designed around the family’s specific rearrangement rather than applied as a standard panel.

If you are weighing PGT-A against PGT-M in the context of a balanced translocation, that comparison has its own considerations and is worth reading separately. What matters here is that a targeted rearrangement test and a general chromosome-number test are not substitutes for one another.

Why the test has to be designed around your karyotype

This is the part that most surprises patients. PGT-SR is not ordered like a standard blood count. Before an assay can be built, the laboratory needs a clear picture of the rearrangement: which chromosomes are involved, where the breakpoints sit, and how the rearranged chromosomes can be reliably told apart from normal ones in a single embryo cell.

That usually means the parental karyotype report is essential, and in some situations additional characterisation of the rearrangement may be requested. The purpose is technical: to establish that the test can actually distinguish the arrangements it is meant to detect. If the rearrangement cannot be adequately characterised, a laboratory may be unable to design a reliable targeted test, and that is a laboratory and clinical judgement rather than something a coordination service can settle.

This is also why timing matters. Assay design and validation take place before the embryo biopsy results can be interpreted, so the conversation about whether PGT-SR is feasible should happen early in IVF planning, not after stimulation has begun.

What PGT-SR can and cannot tell you

A useful way to think about scope is to separate the question the test was built to answer from the questions it was not built to answer.

What it targets: whether the embryo’s sample shows the known rearrangement in a balanced or unbalanced form, based on the assay designed for that family.

What it does not automatically cover: chromosome-number problems elsewhere in the genome. A targeted rearrangement test is not the same as genome-wide aneuploidy screening unless the laboratory’s design explicitly combines the two. If you want to know whether your planned test includes that broader assessment, that is a direct question for the clinical team and laboratory.

What no PGT test can promise: a successful pregnancy, a live birth, or a healthy child. The HFEA is explicit that PGT-A results do not guarantee a successful pregnancy or a healthy child, and the same caution applies to reading any PGT result as a guarantee. A test result describes the cells that were sampled; it does not certify the whole embryo or the whole pregnancy.

There is also a sampling dimension. The HFEA notes that embryo biopsy can cause damage and prevent further development. That risk is one input into the decision, not a reason on its own to accept or decline testing.

The counselling conversation: carrier status, reproductive risk and test limits

Carrier status is often discovered at an unexpected moment — after a pregnancy loss, during investigation of infertility, or through family screening. Learning that you carry a structural rearrangement can be unsettling, and the information is easy to misread. A balanced rearrangement in a parent does not mean the parent has a chromosome abnormality in the everyday sense of being unwell; it means the arrangement of chromosome material is different, and that this can affect how chromosomes are passed on.

Counselling is where the individual picture is worked through: what the rearrangement is, what is known about its reproductive implications for this particular carrier, what testing could and could not show, and what the alternatives are. The HFEA’s position is that a treating team and genetic counsellor should discuss the relevant history, test design and suitability — which is a clinical conversation, not a coordination task.

Patients are entitled to ask licensed clinicians direct questions about their own diagnosis, their options, the risks, how to read a report, and their individual chances. A coordination service can help organise records and relay questions, but it does not diagnose, interpret results or prescribe.

Practical questions about testing scope

When you speak with the clinical team, the most useful questions tend to be about scope rather than about the name of the test:

• Has my rearrangement been fully characterised, and is that information sufficient for the laboratory to design a targeted test?
• Does the planned test look only at the known rearrangement, or does it also assess chromosome number more broadly?
• What would a balanced result mean in our situation, and what would an unbalanced result mean?
• What are the alternatives if a targeted test cannot be designed, or if we choose not to test?
• What is the biopsy risk in our case, and how does the team weigh it?
• Who will explain the report to us, and in what language will that discussion happen?

These are clinical questions. The answers depend on your karyotype, your history and the laboratory’s capabilities, and they should come from the treating team.

Where coordination helps, and where it stops

For international patients, the practical friction around PGT-SR is often administrative: getting the karyotype report and any prior genetic records into the right hands, confirming whether a remote consultation can cover test design, checking what a quotation includes, and arranging for results and follow-up questions to be communicated after you return home. A coordination service can help organise records, request documents, coordinate appointments and clarify what has and has not been confirmed. It cannot tell you whether PGT-SR is right for you, interpret your report, or promise an outcome.

If you are still at the stage of comparing clinics, the countrywide and Bangkok-wide shortlist guides are places to research options; they are editorial comparisons, not evidence that any provider produces better outcomes. For adjacent reading, the guide to PGT-A versus PGT-M for balanced translocation carriers covers a related decision, and the PGT-A explainer sets out what general chromosome screening can and cannot tell you.

Sources: Embryo biopsy can cause damage and prevent further development. — HFEA PGT-A frequently asked questions (checked 2026-10-15).